CA2552404A1 - Methods and compositions for the treatment of lipodystrophy - Google Patents

Methods and compositions for the treatment of lipodystrophy Download PDF

Info

Publication number
CA2552404A1
CA2552404A1 CA002552404A CA2552404A CA2552404A1 CA 2552404 A1 CA2552404 A1 CA 2552404A1 CA 002552404 A CA002552404 A CA 002552404A CA 2552404 A CA2552404 A CA 2552404A CA 2552404 A1 CA2552404 A1 CA 2552404A1
Authority
CA
Canada
Prior art keywords
statin
growth hormone
hgh
lipodystrophy
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002552404A
Other languages
English (en)
French (fr)
Inventor
Giampiero De Luca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2552404A1 publication Critical patent/CA2552404A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002552404A 2004-01-29 2005-01-26 Methods and compositions for the treatment of lipodystrophy Abandoned CA2552404A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54020404P 2004-01-29 2004-01-29
US60/540,204 2004-01-29
US54336604P 2004-02-10 2004-02-10
US60/543,366 2004-02-10
PCT/EP2005/000758 WO2005074916A1 (en) 2004-01-29 2005-01-26 Methods and compositions for the treatment of lipodystrophy

Publications (1)

Publication Number Publication Date
CA2552404A1 true CA2552404A1 (en) 2005-08-18

Family

ID=34841102

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002552404A Abandoned CA2552404A1 (en) 2004-01-29 2005-01-26 Methods and compositions for the treatment of lipodystrophy

Country Status (10)

Country Link
EP (1) EP1722778A1 (pt)
JP (1) JP2007519669A (pt)
KR (1) KR20060127977A (pt)
AU (1) AU2005210093A1 (pt)
BR (1) BRPI0507302A (pt)
CA (1) CA2552404A1 (pt)
EA (1) EA200601392A1 (pt)
IL (1) IL176762A0 (pt)
NO (1) NO20063279L (pt)
WO (1) WO2005074916A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
JP5570999B2 (ja) * 2008-01-03 2014-08-13 ユニベルシテ デ―マルセイユ 抗hiv治療の際に使用される組成物
WO2010121352A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
JP6712230B2 (ja) * 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803623D0 (sv) * 1998-10-22 1998-10-22 Sahltech Ab New therapeutic application

Also Published As

Publication number Publication date
IL176762A0 (en) 2006-10-31
WO2005074916A1 (en) 2005-08-18
KR20060127977A (ko) 2006-12-13
BRPI0507302A (pt) 2007-06-26
JP2007519669A (ja) 2007-07-19
EP1722778A1 (en) 2006-11-22
EA200601392A1 (ru) 2006-12-29
AU2005210093A1 (en) 2005-08-18
NO20063279L (no) 2006-09-19

Similar Documents

Publication Publication Date Title
US20220152160A1 (en) Dosing regimen
US20070161551A1 (en) Methods and compositions for the treatment of lipodystrophy
US6939853B2 (en) Combined use of a GLP-1 compound and another drug for treating dyslipidemia
EP1461070B1 (en) Combined use of a glp-1 compound and an aldose reductase inhibitor
JP5161412B2 (ja) Glp−1及びglp−2ペプチドの使用方法
US20080004217A1 (en) Treatment of hiv-associated dysmorphia/dysmetabolic syndrome (hadds) with or without lipodystrophy
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
EP1515749B1 (en) Combined use of a modulator of cd3 and a glp-1 compound
US20120219603A1 (en) Use of Calcitonin for the Treatment of RA
US8748375B2 (en) Methods for affecting body composition using amylin agonists
JPH11505265A (ja) Igf−iの投与法
CA2552404A1 (en) Methods and compositions for the treatment of lipodystrophy
JP2004518756A (ja) Glp−1類似体およびpparリガンドの誘導体の組み合わせ使用
US20070037861A1 (en) Enhanced method of treatment of growth disorders
MXPA06007761A (en) Methods and compositions for the treatment of lipodystrophy
WO2006133477A1 (en) Peptides corresponding to human growth hormone
EP1229927B1 (en) Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety
MXPA06002948A (en) Enhanced method of treatment of growth disorders
CN1917871A (zh) 治疗脂肪营养不良的方法和组合物
JP2000191549A (ja) Hivに関連した異形症/代謝不全症候群の治療
JPH07316071A (ja) 筋ジストロフィー治療薬

Legal Events

Date Code Title Description
FZDE Discontinued